Members,
A series of multi-day gainers has brought us substantial profit as of late.
Our alert from June 16, 2015, went into full beast mode last week, recently hitting a new 52-week high of $5.58 per share for a realistic +1,353.12% gain!
Our pick from last Monday has as moved higher, hitting a new high of $1.74 per share just two days ago for +27.94% in true profit!
This Monday's alert was also a multi-day runner, hitting a new high price of $2.00 today for a realistic gain of +12.99%!
Are you ready to carry our winning momentum into Thursday? We hope so!
Our analysts have discovered a micro float, IPO-style opportunity that is jam-packed with profit potential.
Immediately turn your attention to MEDH (MedX Holdings Inc.).
MEDH is a U.S. holding company that uses a specific approach to target acquisitions of undervalued, turnaround medical related businesses.
The company provides seasoned professionals in the Healthcare Sector and veterans in medical management, sales and practice with over 35 years of experience.
The “collaborative profit” approach is MEDH’s preferred acquisition method.
The concept behind 'Collaborative Profit' is to be mutually beneficial to all parties while leaving the control of the small business in the hands of the business owner. A management agreement transfers the rights and privileges that were in place prior to acquisition, back to the business owner. Essentially, the operations, accounts and administrative practices are in the hands of the business owner after the acquisition while MEDH manages the public company and over sees all management.
Recent Development(s):
MEDH Announces It Has Entered Into The Pharmaceutical and Nutraceutical Wholesale Distributor Sector
On May 17, 2016, MEDH announced that it is in the process of becoming licensed as a Wholesale Distributor of Pharmaceuticals in the state of Alabama. As a result, the company has also entered into an Exclusive Marketing Agreement with B&B Consulting whose sales exceeded over $7,000,000 dollars in pharmaceutical sales in 2015. Mr. Hiltz, Managing Member of B&B Consulting has agreed to oversee the company’s pharmaceutical sales division. Mr. Hiltz stated “I am excited to join MedX Holdings, I believe that the combination of a public company and pharmaceutical sales just makes sense.”
In addition, MEDH has also secured an agreement with one of the largest FDA Manufacturers in the United States. Our first product that has been approved to sell is a 5% Lidocaine Ointment 50g jar. Our negotiated price allows us to have very competitive pricing to offer B&B’s current list of clients. 5% Lidocaine is a highly sought after analgesic ointment for the purpose of reducing and controlling pain. This comes at a time when our nation is riveting over the rising deaths occurring in epidemic proportion all resulting from the overuse of oral prescription pain medication. As a result, Physicians and other medical professionals are being forced to look at alternative solutions when treating pain.
Kathleen Roberton CEO of MEDH stated, “It makes perfect sense to enter into Pharmaceutical and Nutraceutical sales as we build our portfolio of medial businesses. This will allow our company to produce its own revenue without being a burden to our acquisitions which add tangilble asset based value”.
MEDH Announces the Hiring of a Certified Designated Representative
MEDH announced earlier today that Mr. Charles Yelton R.Ph has joined its team as Vice President in charge of Nutraceutical and Pharmaceutical Development.
In addition to this position as a licensed pharmacist, he will also serve as MEDH's Certified Designated Representative.
Mr. Yelton has been a licensed pharmacist for over 39 years. He previously owned Carpenter Dent Drugs where he successfully grew this business from $146,000 to over $1,200,000 annually. After 23 years, he sold this business and went to work as a pharmacist for a major retail chain; he has worked in over 115 pharmacies throughout Kentucky and Alabama. Mr. Yelton was also the creator of Pain Doctor, an external OTC analgesic for pain distributed by ABC Pharmaceuticals.
Ms. Roberton, CEO of MEDH commented: “We are very pleased to have Mr. Yelton join our team, I have personally had the pleasure of knowing him and his integrity for almost 10 years. Mr. Yelton’s experience and knowledge both as a licensed pharmacist and owner of ABC Pharmaceuticals is exactly what we needed to move forward as a licensed wholesale distributor of pharmaceuticals in many states.”
Charles Yelton R.Ph, offered: “I am excited to join this talented MEDH team. Together, we have the potential to create extreme dynamic sales growth very quickly. We are working with one the top pharmaceutical manufactures who holds over 105 ANDA’s which allows us to expand our projected RX lines and OTC lines very quickly.”
Licensing Update: MEDH is in the final stages of securing a warehouse/office space in the state of Alabama, as well as in the state of Florida. The company will be fully licensed as a Wholesale Distributor of Pharmaceuticals in Alabama where Mr. Yelton works and is currently licensed. In Florida, the company will ship directly to a Third Party Logistic partner who will legally ship to all of the clients in Florida. A Third Party Logistic Warehouse represents the fastest path for MEDH to legally sell in the state of Florida. A 3PL does not manufacture the products, take title to own the products nor has anything to do with selling the products. The company's partner will simply take possession, repackage if necessary, and then ship directly to clients.
Market Outlook:
Lidocaine is a highly sought after anesthetic, or numbing medication, commonly used for relieving pain in the mouth and throat and reliving pain and/or itching associated with minor cuts, scrapes, burns, or irritations on the skin.
According to a report by Allied Market Research, the global analgesics market is estimated to total $26.4 billion by 2022.
North America and Europe collectively account for over 50% of the global analgesics market.
The U.S. occupies a majority of the North American global analgesics market.
The global pharmaceutical market generates revenues exceeding $1 trillion.
North America alone generates over 40% of the revenues.
Technical Analysis:
MEDH has recently demonstrated its ability to move up the chart very quickly on lighter volume.
Looking at the company's 1-month chart, you will notice that MEDH has moved from $0.10 to $0.80 per share on very little trading volume.
In fact, MEDH closed today's session +2.5% at $0.82 per share on a measly 1,300 shares trade.
Here's the thing to keep in mind...
This is a relatively new company and there are very little technicals to play on, however...
According to TDAmeritrade Research, MEDH has a float of only 163.1K shares.
That's the equivalent of only $133.7K in shares available to the entire public for trading!
We are confident that a sudden boost in volume will send shares of MEDH soaring up the chart tomorrow!
That having been said, we ask that you continue your research on MEDH and if you choose, be ready to trade when the market opens at 9:30am EST.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
